Cargando…

Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus

The Australian paralysis tick Ixodes holocyclus continues to be a serious threat to companion animals along Australia’s east coast. The tick produces a potent neurotoxin which causes a rapidly ascending flaccid paralysis, which if left untreated, can result in the death of the animal. There is curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeber, Florian, Jackson, Chrissie, Chambers, Michael, Smith, Veronica, Hume, Jane, Blazejak, Katrin, Mencke, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320399/
https://www.ncbi.nlm.nih.gov/pubmed/37416339
http://dx.doi.org/10.1016/j.crpvbd.2023.100123
_version_ 1785068444926869504
author Roeber, Florian
Jackson, Chrissie
Chambers, Michael
Smith, Veronica
Hume, Jane
Blazejak, Katrin
Mencke, Norbert
author_facet Roeber, Florian
Jackson, Chrissie
Chambers, Michael
Smith, Veronica
Hume, Jane
Blazejak, Katrin
Mencke, Norbert
author_sort Roeber, Florian
collection PubMed
description The Australian paralysis tick Ixodes holocyclus continues to be a serious threat to companion animals along Australia’s east coast. The tick produces a potent neurotoxin which causes a rapidly ascending flaccid paralysis, which if left untreated, can result in the death of the animal. There is currently only a limited number of products registered in Australia for the treatment and control of paralysis ticks in cats. Felpreva® is an effective spot-on combination containing emodepside, praziquantel and tigolaner. To investigate the therapeutic and long-term persistent efficacy of Felpreva® (2.04% w/v emodepside, 8.14% w/v praziquantel and 9.79% w/v tigolaner) against experimental infestation with I. holocyclus in cats, two studies were undertaken. Fifty cats were included in the studies on study Day -17. These cats were immunized against paralysis tick holocyclotoxin prior to the study commencing. Immunity to holocyclotoxin was confirmed with a tick carrying capacity (TCC) test conducted prior to treatment. Cats were treated once on Day 0. Group 1 cats were treated with the placebo formulation and Group 2 cats were treated with Felpreva®. Cats were infested on Days -14 (tick carrying capacity test), 0, 28, 56, 70, 84 and 91 (weeks 4, 8, 10, 12 and 13). Ticks were counted on cats 24 h, 48 h and 72 ​h post-treatment and infestation, except during the tick carrying capacity test when they were counted approximately 72 ​h post-infestation only. The 24-h and 48-h assessments were conducted without removing the ticks. The ticks were assessed, removed and discarded at the 72-h assessment time-points. Significant differences in total live tick counts at ∼24 h, ∼48 h and ∼72 ​h post-infestation were observed between the treatment and control group. Differences were significant (P ​< ​0.05 to ​< ​0.001) in all instances. Treatment efficacies of 98.1–100% were observed ∼72 ​h post-infestation through to 13 weeks (94 days) post-treatment. These results show that a single application of Felpreva® provides effective treatment and control against induced infestation with paralysis ticks for 13 weeks.
format Online
Article
Text
id pubmed-10320399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103203992023-07-06 Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus Roeber, Florian Jackson, Chrissie Chambers, Michael Smith, Veronica Hume, Jane Blazejak, Katrin Mencke, Norbert Curr Res Parasitol Vector Borne Dis Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova The Australian paralysis tick Ixodes holocyclus continues to be a serious threat to companion animals along Australia’s east coast. The tick produces a potent neurotoxin which causes a rapidly ascending flaccid paralysis, which if left untreated, can result in the death of the animal. There is currently only a limited number of products registered in Australia for the treatment and control of paralysis ticks in cats. Felpreva® is an effective spot-on combination containing emodepside, praziquantel and tigolaner. To investigate the therapeutic and long-term persistent efficacy of Felpreva® (2.04% w/v emodepside, 8.14% w/v praziquantel and 9.79% w/v tigolaner) against experimental infestation with I. holocyclus in cats, two studies were undertaken. Fifty cats were included in the studies on study Day -17. These cats were immunized against paralysis tick holocyclotoxin prior to the study commencing. Immunity to holocyclotoxin was confirmed with a tick carrying capacity (TCC) test conducted prior to treatment. Cats were treated once on Day 0. Group 1 cats were treated with the placebo formulation and Group 2 cats were treated with Felpreva®. Cats were infested on Days -14 (tick carrying capacity test), 0, 28, 56, 70, 84 and 91 (weeks 4, 8, 10, 12 and 13). Ticks were counted on cats 24 h, 48 h and 72 ​h post-treatment and infestation, except during the tick carrying capacity test when they were counted approximately 72 ​h post-infestation only. The 24-h and 48-h assessments were conducted without removing the ticks. The ticks were assessed, removed and discarded at the 72-h assessment time-points. Significant differences in total live tick counts at ∼24 h, ∼48 h and ∼72 ​h post-infestation were observed between the treatment and control group. Differences were significant (P ​< ​0.05 to ​< ​0.001) in all instances. Treatment efficacies of 98.1–100% were observed ∼72 ​h post-infestation through to 13 weeks (94 days) post-treatment. These results show that a single application of Felpreva® provides effective treatment and control against induced infestation with paralysis ticks for 13 weeks. Elsevier 2023-05-30 /pmc/articles/PMC10320399/ /pubmed/37416339 http://dx.doi.org/10.1016/j.crpvbd.2023.100123 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova
Roeber, Florian
Jackson, Chrissie
Chambers, Michael
Smith, Veronica
Hume, Jane
Blazejak, Katrin
Mencke, Norbert
Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title_full Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title_fullStr Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title_full_unstemmed Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title_short Efficacy and safety of Felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the Australian paralysis tick Ixodes holocyclus
title_sort efficacy and safety of felpreva®, a spot-on formulation for cats containing emodepside, praziquantel and tigolaner against experimental infestation with the australian paralysis tick ixodes holocyclus
topic Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320399/
https://www.ncbi.nlm.nih.gov/pubmed/37416339
http://dx.doi.org/10.1016/j.crpvbd.2023.100123
work_keys_str_mv AT roeberflorian efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT jacksonchrissie efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT chambersmichael efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT smithveronica efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT humejane efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT blazejakkatrin efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus
AT menckenorbert efficacyandsafetyoffelprevaaspotonformulationforcatscontainingemodepsidepraziquantelandtigolaneragainstexperimentalinfestationwiththeaustralianparalysistickixodesholocyclus